



ABN 53 075 582 740

ASX ANNOUNCEMENT

1 July 2021

APPOINTMENT AND RESIGNATION OF DIRECTOR

Bionomics Limited (ASX:BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company, announced today that Mr Miles Davies has been appointed Non-Executive Director to the Board of Bionomics Limited.

Mr Davies replaces Dr. Srinivas Rao as the second Board nominee of Apeiron Investment Group Ltd ("Apeiron") under the Subscription Agreement dated 1 June 2020 between the Company and Apeiron.

Mr Davies is a 15-year veteran of the financial services industry with deep multi-sector and multi-function experience. He has a proven track record in advising private and public company Board of Directors and shareholders of businesses that range in Enterprise Value size of \$100m to \$5bn. He has completed numerous M&A transactions across a variety of sectors including healthcare, along with strong experience in capital raising and restructuring opportunities during his time at Rothschild & Co.

Mr Davies is currently an Investment Professional at Apeiron Investments Group and is Chief Business Officer for Leaf4Life Inc.

The Board would like to thank Dr Rao for his dedication and service and wishes him well for the future.

Released on authority of the Board.

FOR FURTHER INFORMATION PLEASE CONTACT:

Ms Suzanne Irwin
Company Secretary
+61 8 8150 7400
CoSec@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO, OTCQB: BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease.

www.bionomics.com.au